megestrol acetate + standard therapy

Megestrol acetate + standard therapy is an investigational combination regimen being developed by Changchun GeneScience Pharmaceutical Co., Ltd. for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy. The regimen consists of megestrol acetate oral suspension added to standard antiemetic therapy, which typically includes 5-HT3 receptor antagonists and dexamethasone. Megestrol acetate is a synthetic progesterone derivative (17α-hydroxyprogesterone) that has traditionally been used to treat cancer-associated anorexia and cachexia but has demonstrated antiemetic properties in clinical settings. The combination is currently being evaluated in Phase Ib clinical trials to determine its efficacy, safety, and pharmacokinetic profile in patients with malignant solid tumors, such as lung cancer, undergoing emetogenic chemotherapy regimens.

Other names

megestrol acetate oral suspension